Strategic Investors Can Be White Knights

Despite the current financing crisis, strategic investors are still doing deals. Eli Lilly and Amylin recently entered into a licensing agreement for the rights to Altea Therapeutics‘ exenatide transdermal patch technology. The deal includes an upfront licensing payment, regulatory and sales milestones of up to $46 million, and royalties. Lilly and Amylin also made an equity investment in Altea. My friends in business development at biopharma and medical device companies have said that they are still looking to do deals, but they also know that valuations are lower and it’s a buyers market. No point in rushing into a deal when they know that a startup doesn’t have too many alternatives to financing.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: